Retroviral and Lentiviral Vectors to Increase Efficiency of Inducible Pluripotent Stem Cell (iPSC) Production
Posted Jun 20 2013 8:00pm
Description of Invention: Researchers at the National Cancer Institute have discovered that modulating a specific p53 isoform increases the number of inducible pluripotent stem cells that can be obtained from cells that are being re-programmed to obtain pluripotent cells. It is known that the activity of p53 regulates the self-renewal and pluripotency of normal and cancer stem cells, and also affects re-programming efficiency of iPS cells. This p53 isoform-based technology provides a more natural process of increasing iPS cell production than previous methods of decreasing p53.
Stem cell-based regenerative medicine
Cancer therapeutic that targets cancer stem cells
Advantages: The retroviral and lentiviral vectors in this invention allow more selective control of p53 activities than siRNA or mutant p53 methods.
Related international patent applications are pending.
Related Technologies: US, Application No. 12/742,250 filed 10 May 2010, Reference No. E-033-2008/0 EIR, Reference No. E-137-2010/0 - Research Tool. Patent protection is not being pursued for this technology. US, Application No. 60/987,340 filed 12 Nov 2007, Reference No. E-033-2008/0
Collaborative Research Opportunity: The National Cancer Institute, Laboratory of Human Carcinogenesis, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Retroviral and Lentiviral Vectors. For collaboration opportunities, please contact John D. Hewes, Ph.D. at firstname.lastname@example.org .
For Licensing Information Please Contact: Patrick McCue Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: McCuepat@mail.nih.gov Phone: 301-496-7057 Fax: 301-402-0220